Drug
Lutetium 177lu Oxodotreotide
Lutetium 177lu Oxodotreotide: highest development phase Phase 3, developed by Sinotau Pharmaceutical Group. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sinotau Pharmaceutical Group
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lutetium[177Lu] Oxodotreotide Injection NCT05459844 | Phase 3 | Neuroendocrine Tumors |
Latest
No recent events.
Follow Lutetium 177lu Oxodotreotide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.